Natco Pharma Ltd. (NATCOPHARM) 52 Week Low Streak extends to second straight session
- October 9, 2026
- Posted by: Chaitanya Auti
- Category: News
Natco Pharma Ltd. 52 Week Low Streak has now extended to a second straight session, with the stock trading within 2% of its 52-week low across both days. Across the streak, the share price has moved down 2.23%, and the latest trading print stood at Rs 792.1. The latest Univest data confirms the repeated-low pattern, but it does not establish a company-specific cause for the continued weakness.
At 9:52 AM IST, Natco Pharma Ltd. share price today was at Rs 792.1 versus the previous close of Rs 796, a fall of Rs 3.9 or 0.49%. The stock opened at Rs 796, touched a high of Rs 800 and a low of Rs 788, placing the current level near the lower end of the intraday range. The company’s market capitalisation stood at Rs 15,893.53 crore, so the Natco Pharma Ltd. share price update remains relevant for readers tracking repeated yearly-low behaviour rather than a single-day move.
Natco Pharma Ltd. 52 Week Low Streak: Consecutive Low Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 792.1 |
| Previous Close | Rs 796 |
| Today's Move | Rs -3.9 (-0.49%) |
| Open | Rs 796 |
| High | Rs 800 |
| Low | Rs 788 |
| Market Capitalisation | Rs 15,893.53 crore |
Natco Pharma Ltd. (NATCOPHARM) traded at Rs 792.1 versus the previous close of Rs 796, a fall of 0.49%. The stock opened at Rs 796, reached a high of Rs 800, touched a low of Rs 788.
Natco Pharma Ltd. share price today is still trading below the previous close, keeping the stock in a weak intraday position after another session near its 52-week trough. The current price of Rs 792.1 compares with the previous close of Rs 796, reflecting a modest decline of Rs 3.9 or 0.49%. The stock opened exactly at Rs 796, briefly moved to Rs 800, and slipped to Rs 788, which shows that the day’s range has remained narrow and tilted toward the lower end. For readers following Natco Pharma Ltd. stock news, the key point is not a sharp one-day shock but the persistence of weakness across consecutive sessions.
The repeated proximity to the yearly low makes this Natco Pharma Ltd. stock analysis different from a normal share price update. The first sign of breakdown came in the prior session, and today’s print has extended that pattern without confirming any fresh trigger. Natco Pharma Ltd. stock performance should therefore be read as a continuing near-low trade rather than an isolated dip. With market capitalisation at Rs 15,893.53 crore, the Natco Pharma Ltd. market cap places it among larger listed pharma names, but size alone does not change the fact that the Natco Pharma Ltd. share price remains under pressure. This is why Natco Pharma Ltd. NSE and Natco Pharma Ltd. BSE watchers are treating the move as a developing streak.
What the Repeated 52-Week Lows Show
Natco Pharma Ltd. 52 Week Low Streak matters because it shows persistence, not just a one-off fluctuation. A stock that trades within 2% of its one-year low for a second straight session tells readers that the weakness has not faded between trading days. In this case, the cumulative move across the streak is already -2.23%, which is more useful than a single-day percentage because it captures the full repeated-low pattern. Natco Pharma Ltd. New One Year Low searches and Natco Pharma Ltd. Back To Back 52 Week Lows queries are both aligned with this exact setup.
The latest pattern also leaves a clear interpretive boundary. Univest data confirms the repeated 52-week low streak, but it does not establish a company-specific cause for why Natco Pharma Ltd. keeps trading near the one-year trough. That distinction matters for Natco Pharma Ltd. stock news readers who may otherwise try to connect the move to a single event. The correct reading is that the Natco Pharma Ltd. 52 Week Low Streak reflects extended price weakness, while the reason for the weakness is not confirmed by the numbers alone. Investors scanning Stocks Hitting 52 Week Lows or Stocks At One Year Low Today should treat this as a pattern watch, not a narrative conclusion.
Natco Pharma Ltd. (NATCOPHARM) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 15,893.53 crore |
| P/E Ratio | 13.65x |
| P/B Ratio | 1.67x |
| ROE | 16.3% |
| ROCE | 17.16% |
| EPS | Rs 58.33 |
| Book Value Per Share | Rs 476.47 |
| Dividend Yield | 0.62% |
Natco Pharma Ltd. (NATCOPHARM) fundamental metrics show P/E 13.65x, P/B 1.67x, ROE 16.3%, ROCE 17.16%. These figures provide context only and are not a buy or sell signal.
Natco Pharma Ltd. has a market capitalisation of Rs 15,893.53 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 13.65x, P/B at 1.67x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 16.3% and ROCE of 17.16%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 58.33, book value per share of Rs 476.47, dividend yield of 0.62%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 27.13x, median ROE of 11.48%, median ROCE of 13.28%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 13.65x |
| Benchmark Median P/E | 27.13x |
| Benchmark Average P/E | 40.12x |
| Benchmark P/E Range | 0x to 678.22x |
| Company P/B Ratio | 1.67x |
| Benchmark Median P/B | 2.81x |
| Company ROE | 16.3% |
| Benchmark Median ROE | 11.48% |
| Company ROCE | 17.16% |
| Benchmark Median ROCE | 13.28% |
| Company Market Capitalisation | Rs 15,893.53 crore |
| Benchmark Median Market Cap | Rs 803.77 crore |
Natco Pharma Ltd. (NATCOPHARM) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Natco Pharma Ltd. (NATCOPHARM) has a P/E ratio of 13.65x, which is below the benchmark median of 27.13x, a difference of -49.69%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Natco Pharma Ltd. (NATCOPHARM) has a ROE of 16.3%, which is above the benchmark median of 11.48%, a difference of +41.99%. Natco Pharma Ltd. (NATCOPHARM) has a ROCE of 17.16%, which is above the benchmark median of 13.28%, a difference of +29.22%.
Track stocks falling to yearly lows through the Univest 52-week-low screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Eris Lifesciences Ltd. | ERIS | 15,911.93 | 24.76 | 3.95 | 19.23 | 14.47 |
| Jubilant Pharmova Ltd. | JUBLPHARMA | 15,517.96 | 42.17 | 2.08 | 5.97 | 8.69 |
| Alembic Pharmaceuticals Ltd. | APLLTD | 16,374.69 | 22.69 | 2.69 | 12.35 | 11.74 |
| Glenmark Life Sciences Ltd. | ALIVUS | 16,423.75 | 27.24 | 4.71 | 18.41 | 24.61 |
| Marksans Pharma Ltd. | MARKSANS | 14,741.42 | 27 | 4.39 | 15.31 | 21.1 |
Natco Pharma Ltd. (NATCOPHARM) has a P/E ratio of 13.65x compared with the displayed peer median of 27x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 16.3% compares with a peer median of 15.31% across the companies shown in the table. ROCE stood at 17.16% versus the displayed peer median of 14.47%, providing a capital-efficiency comparison. Natco Pharma Ltd. (NATCOPHARM) has a market capitalisation of Rs 15,893.53 crore. Among the 5 peers shown, 3 have a larger market capitalisation.
Why Investors Are Watching
- Natco Pharma Ltd. 52 Week Low Streak is now at a second straight session, which keeps the yearly-low pattern in focus.
- The Natco Pharma Ltd. share price has moved -2.23% across the streak, making the repeated-low move more important than one isolated print.
- Natco Pharma Ltd. Fundamental Analysis shows a P/E and P/B below the industry median, which helps frame the stock’s valuation backdrop.
- The Natco Pharma Ltd. market cap of Rs 15,893.53 crore places it among significant listed pharma names in Healthcare.
- Readers tracking Natco Pharma Ltd. Stock News will want to watch whether the repeated low pattern continues or stabilises in the next few prints.
About the Company
Natco Pharma Ltd. operates in the Pharmaceuticals & Drugs industry within the Healthcare sector. The business is listed on NSE and BSE and is followed by investors who track Natco Pharma Ltd. share price, Natco Pharma Ltd. stock performance and Natco Pharma Ltd. stock news alongside broader sector developments. Based on the Univest metrics, the company shows a market capitalisation of Rs 15,893.53 crore, P/E of 13.65, P/B of 1.67, ROE of 16.3%, ROCE of 17.16%, EPS of Rs 58.33 and book value of Rs 476.47.
The Natco Pharma Ltd.For readers following the Natco Pharma Ltd. 52 Week Low Streak, the important point is that the company remains a significant pharma name even while trading near its yearly low for back-to-back sessions.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Registration Number INH000013776), a subsidiary of Univest Communication Technologies Private Limited.
Frequently Asked Questions
What does Natco Pharma Ltd. 52 Week Low Streak mean?
Ans. It means Natco Pharma Ltd. has traded within 2% of its 52-week low for a second straight session. The pattern points to repeated weakness near the yearly low, not necessarily a fresh breakdown below it.
How many sessions has Natco Pharma Ltd. stayed near its yearly low?
Ans. Natco Pharma Ltd. has now stayed within 2% of its 52-week low for two consecutive sessions. That is why this is described as a second straight session in the Natco Pharma Ltd. 52 Week Low Streak.
What is the cumulative move across the Natco Pharma Ltd. 52 Week Low Streak?
Ans. The cumulative change across the streak is -2.23%. This is the best way to read the repeated-low pattern because it captures the full move over the two sessions, not only the latest print.
How does Natco Pharma Ltd. compare on valuation with peers?
Ans. Natco Pharma Ltd. trades at a P/E of 13.65 and P/B of 1.67, both below the industry median in the supplied comparison set. That makes the valuation look lower than several peer names in the same Pharmaceuticals & Drugs group.
What should investors monitor next in Natco Pharma Ltd. stock news?
Ans. Investors should monitor whether Natco Pharma Ltd. continues to trade near the 52-week low or starts moving away from it. The next prints will help show whether the Natco Pharma Ltd. 52 Week Low Streak extends further or stabilises.
Is Natco Pharma Ltd. part of the Stocks Hitting 52 Week Lows category?
Ans. Yes, based on the current pattern it fits the broader Stocks Hitting 52 Week Lows theme because it is trading within 2% of its yearly low for consecutive sessions. The key distinction is the repeated streak, not just a single-day.
Track Natco Pharma Ltd. (NATCOPHARM) Share Price on Univest
Use Natco Pharma Ltd. (NATCOPHARM) live share-price page, Univest 52-week-low screener, Univest market blogs to review live stock data, yearly-low lists and related market analysis.